In 2022, US president Joe Biden’s Inflation Reduction Act (IRA) introduced a mechanism for the state-backed health insurance programme Medicare to negotiate drug prices directly with pharmaceutical firms. The industry’s response was scathing, with lawsuits claiming the move was unconstitutional, and dire warnings of stifling innovation and R&D investment. With negotiations on the first batch […]
Read More